# KLOW Peptide Research: Component Studies & Mechanisms | Safe KLOW > KLOW peptide research indexed by component: KPV NF-kappaB studies, GHK-Cu transcriptome and collagen findings, BPC-157 tendon and muscle models, TB-500 wound-healing data. All claims cited. Four constituents, four separate ledger folios. Each finding attributed to its source component. The combination record filed as absent. ## In plain English KLOW peptide is made of four research compounds that each have their own set of studies. This page summarizes what those studies found. The research is almost entirely in animals — mice and rats, mostly — with a small number of human experiments for individual components. There is no human study of the four compounds together. KPV is a tiny peptide (three amino acids long) that damps down inflammation in gut and immune cells — it blocks a molecular switch called NF-kappaB that turns on inflammatory genes. GHK-Cu is a copper-carrying tripeptide that influences how fibroblasts (the cells that build connective tissue) express genes related to collagen and repair. BPC-157 is a 15-amino-acid peptide with a sizable animal literature on tendon and muscle healing. TB-500 is a short peptide fragment linked to wound closure and cell movement. Every finding below is labeled with its source compound, its species, and its citation. Where the blend combination has no data, that is stated plainly. ## TB-500: wound healing and re-epithelialization In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at day 4 and up to 61% at day 7 versus saline [1]. Wound contraction improved by at least 11% by day 7, and collagen deposition and angiogenesis were elevated. As little as 10 picograms stimulated keratinocyte (skin surface cell) migration two-to-three-fold in assay. Important context: the TB-500 component is the short LKKTET heptapeptide fragment, not the full-length 43-amino-acid thymosin beta-4 native protein. The wound-healing data cited above were generated with the native protein. The fragment carries the same actin-sequestering motif — G-actin sequestration (binding monomeric actin to influence cell migration) is the mechanism [12] — but the full range of activities established for the native protein, including integrin-linked kinase activation and epicardial progenitor mobilization, have not been demonstrated for the heptapeptide fragment. The distinction is required by the literature and is not a minor caveat. A 2026 Sports Medicine review covering both TB-500/thymosin beta-4 and BPC-157 concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [7]. ## BPC-157: tendon, muscle, and bone repair BPC-157 (Body Protection Compound 157, a 15-amino-acid synthetic peptide derived from a gastric-juice protein) accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures at doses of 10 micrograms, 10 nanograms, or 10 picograms per rat administered intraperitoneally once daily; it also stimulated tendocyte (tendon cell) outgrowth in vitro [2]. BPC-157 rescued corticosteroid-impaired muscle healing in rats, restoring recovery toward control levels [8]. In a crush-injury model of the gastrocnemius muscle (the large calf muscle), BPC-157 accelerated functional and structural recovery [9]. In a rabbit segmental bone-defect model, BPC-157 improved healing relative to controls, supporting a role in bone repair [10]. A 2022 review summarized protective and healing effects of BPC-157 across striated, smooth, and heart muscle in rodent models, framing a unifying muscle-protective action [11]. The primary mechanistic pathway is VEGFR2/PI3K/Akt/eNOS — activation of the vascular endothelial growth factor receptor 2 (VEGFR2) cascade, which drives angiogenesis (new blood-vessel growth) and downstream nitric-oxide (NO) system modulation. BPC-157 also upregulates the growth-hormone receptor in tendon fibroblasts. A 2026 study documented resolution of a tracheocutaneous fistula (an abnormal channel between windpipe and skin) linked to BPC-157's NO-system effects [14]. Human data are limited: a small 2025 IV safety pilot administered intravenous BPC-157 at 10 mg on day 1 and 20 mg on day 2 to two healthy adults. No adverse events were observed and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers were recorded [6]. This is a two-person, open-label, non-efficacy study — not a controlled trial. ## KPV: NF-kappaB and intestinal anti-inflammation KPV (Lys-Pro-Val, the C-terminal tripeptide of alpha-MSH, the melanocyte-stimulating hormone) is transported into intestinal epithelial cells via the di/tripeptide transporter PepT1 (SLC15A1) with a Michaelis constant (Km) of approximately 160 micromolar, indicating high-affinity substrate recognition [3]. In human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and Jurkat T-cells, nanomolar KPV inhibited NF-kappaB nuclear import, suppressed MAPK ERK/p38 signaling, and reduced secretion of TNF-alpha, IL-6, IL-1beta, and IL-8. In C57BL/6 mice with DSS- and TNBS-induced colitis (two established models of inflammatory bowel disease), oral KPV at 100 micromolar in drinking water reduced colitis severity [3]. PepT1 is upregulated in inflamed intestinal epithelium, giving KPV preferential uptake at the sites of active inflammation — a mechanism relevant to the gut-mucosa primary targets of the blend. No controlled KPV monotherapy trial has reached human approval. ## GHK-Cu: transcriptomics, collagen, and matrix synthesis GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, Copper Tripeptide-1) is the mass-dominant component of the canonical KLOW vial at approximately 50 of 80 mg. First isolated from human plasma by Loren Pickart in 1973, it declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [4]. A 2015 review of clinical and in vitro studies documented stimulation of collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin synthesis; and topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a placebo-controlled comparison [4]. At the transcriptome level, GHK modulates expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, with strongest signals on extracellular-matrix remodeling, ubiquitin-proteasome-system upregulation (41 genes up, 1 down), DNA-repair, and antioxidant gene sets [5]. The widely quoted '~4,000 genes' figure is an extrapolation; the 50% threshold table reports on the order of 2,100 genes [5]. GHK-Cu also supplies copper for lysyl oxidase, the copper-dependent enzyme that crosslinks collagen and elastin into load-bearing connective tissue. A 2023 in vitro study of biotinylated GHK and its copper(II) complex demonstrated antioxidant activity and antiglycant protection against amyloid-beta and acrolein adducts relevant to oxidative neurodegeneration [13]. A 2023 liposomal delivery study achieved 31.7% encapsulation efficiency with no cytotoxicity and 48.9% elastase inhibition in human epidermal cells, supporting liposomal delivery as a viable bioavailability strategy [14]. --- A catalogued index of the four-constituent literature — what each component's studies measured, the blend's combination column filed as the ruled blank it is.